Catalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for RLY-2608 in Vascular Malformations. The expected timing is based on the latest available company guidance and may change.
ReInspire trial. 5/5/25- Trial initiated in Q1'25. 11/06/25:- Trial execution continues. 02/26/26:- Initial data planned H1 2026, about 20 patients including pediatric cohort. 05/05/26:- ISSVA call May 19 to discuss initial clinical results; late-breaking abstract May 20; pre-clinical data on May 22. 05/19/26:- Initial Ph2 ReInspire data reported; expansion cohorts opened; pediatric dose-finding ongoing. 08/06/26:- ReInspire data showed 60% response. Expansion cohorts opened. Data and regulatory update expected Year-End 2026.
Verification
Confirm timing and program details against the company announcement or filing.